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See related research by Wang et al. http://ccforum.com/content/18/5/563A study by Wang and colleagues [1] in a previous issue
of Critical Care shows that heparin may reduce 28-day
mortality in severe sepsis patients without causing an in-
creased risk of bleeding. Therefore, the authors recom-
mend the use of heparin for sepsis and severe sepsis.
Although their result may significantly influence clinical
practice, several confounding factors should be noticed.
In this study, eight studies performed analyses of mor-
tality and seven studies performed analyses of bleeding
events. From Additional file two, three non-randomized
controlled trials (NRCTs) account for 88.42% of weight
on mortality [2-4]; and from Figure three, two NRCTs
account for 92.27% of weight on bleeding events [2,3]. In
other words, the results of this meta-analysis are almost
equivalent to those of the meta-analysis of these five
NRCTs. Given the above analysis, the subgroup analyses
in this study were unnecessary. However, the three stud-
ies were only placebo groups in three large multi-center
randomized controlled trials [2-4]. Patients in these pla-
cebo groups were not randomly assigned to receive hep-
arin or other therapy. In addition, it is possible that
patients receiving heparin were less severe, because the
Acute Physiology and Chronic Health Evaluation II score
was not reported in these placebo groups. Moreover, as
the initial times of heparin treatment were not defined
clearly in the above three studies, we cannot rule out the
possibility that patients who had died early would have
no chance to receive heparin, whereas patients who had
a longer survival would be more inclined to receive hep-
arin. Finally, the dose of heparin in the three trials, and
within each trial, was not controlled.* Correspondence: zmhzjzk@163.com
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